Table 3.
Baseline characteristics in relation to copeptin levels
| Copeptin <13.2 pmol/l (n = 54) | Copeptin >13.2 pmol/l (n = 38) | p-value | |
|---|---|---|---|
| Age (years) |
55.2 (45–67) |
57.4 (50–71) |
0.63 |
| Gender (%female) |
72 |
52 |
0.49 |
| 6MWD [m] |
344 (252–489) |
303 (202–406) |
0.43 |
| NYHA class [%] |
|
|
0.012 |
| II |
32 |
13 |
|
| III |
67 |
76 |
|
| IV |
2 |
11 |
|
| Edema (%) |
35 |
45 |
0.38 |
| S-Na [mmol/l] |
139 (138–143) |
139 (136–141) |
0.46 |
| Creatinine [μg/l] |
87.2 (61–94) |
91.5 (71–105) |
0.04 |
| eGFR (CKD-EPI) [ml/min] |
87 (74–99) |
78 (60–93) |
0.03 |
| NT-proBNP [pg/ml] |
1562 (351–18) |
3057 (1678–4531) |
<0.001 |
| RA [mmHg] |
5.3 (2–8) |
7.8 (2–12) |
0.43 |
| PCWP [mmHg] |
8.8 (6–12) |
8.1 (6–10) |
0.45 |
| mPAP [mmHg] |
45 (32–67) |
46.2 (39–54) |
0.56 |
| CI [ml/min/m2] |
2.5 (1.9-2.9) |
2.2 (1.9-2.9) |
0.12 |
| PVR [dyn · sec · cm-5] |
777 (419–1032) |
814 (541–980) |
0.26 |
| SvO2 [%] | 65 (58–73) | 60 (56–67) | 0.06 |
PAH patients from cohort 1 were dichotomized according their copeptin levels (<13.2 pmol/l or >13.2 pmol/l) and demographic, clinical, biochemical and hemodynamic variables from both groups were compared. Differences were calculated by using Mann–Whitney U-test for continuous and χ2 -test for categorical variables.
Except for sex, NYHA class and edema (%), data are shown as median (interquartile range, IQR).
Definition of abbreviations: 6MWD 6 minute walking distance, NYHA New York Heart Association, S-Na Serum Sodium concentration, eGFR (CKD-EPI) estimated glomerular filtration calculated according the Chronic Kidney Disease Epidemiology Collaboration formula, NT-proBNP N-terminal prohormone of brain natriuretic peptide, RA right atrial pressure, PCWP pulmonary capillary wedge pressure, mPAP mean pulmonary artery pressure, CI cardiac index, PVR pulmonary vascular resistance, SvO2 mixed venous oxygen saturation.